Anemia is a common feature of multiple myeloma. Its causation is multifactorial, but some patients benefit from recombinant human erythropoietin (rHuEpo).
Get full access to this article
View all access options for this article.
References
1.
DurieB.G., SalmonS.E.. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.Cancer.1975; 36: 842–854.
2.
FaquinW.C., SchneiderT.J., GoldbergM.A.. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.Blood.1992; 79: 1987–1994.
3.
BeguinY.. Erythropoiesis and erythropoietin in multiple myeloma.Leuk Lymphoma.1995; 18: 412–421.
4.
BeguinY., VernaM., LooM.. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production.Br J Haematol.1992; 82: 648–653.
5.
SpivakJ.L., PhamT., IsaacsM.. Erythropoietin is both a mitogen and a survival factor.Blood.1991; 77: 1228–1233.
6.
CasatiS., PasseriniP., CampiseM.R.. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.Br Med J.1987; 295: 1017–1020.
7.
TaylorJ., MactireR.A., StewartW.K.. The effect of erythropoietin on anemia in patients with myeloma receiving haemodialysis.Br Med J.1990; 301: 476–477.
8.
LudwigH., FritzE., KotzmannH.. Erythropoietin treatment of anemia associated with multiple myeloma.N Engl J Med.1990; 322: 1693–1699.
9.
BarlogieB.. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.Semin Hematol.1993; 30(4 suppl 6): 25–27.
10.
BarlogieB., BeckT.. Recombinant human erythropoietin and the anemia of multiple myeloma.Stem Cells (Dayt).1993; 11: 88–94.
11.
GartonJ.P., GertzM.A., WitzigT.E.. Epoetin alfa for the treatment of the anemia of multiple myeloma: a prospective, randomized, placebo-controlled, double-blind trial.Arch Intern Med.1995; 155: 2069–2074.
12.
CazzolaM., MessingerD., BattistelV.. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.Blood.1995; 86: 4446–4453.
